Boston Scientific (BSX)
(Delayed Data from NYSE)
$76.51 USD
+0.40 (0.53%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $76.51 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Price, Consensus and EPS Surprise
BSX 76.51 +0.40(0.53%)
Will BSX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BSX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BSX
Medtronic Loses 5% in a Month: What's Next for MDT Investors?
Boston Scientific (BSX) Ascends While Market Falls: Some Facts to Note
BSX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Boston Scientific (BSX) DBS Programming Software Gets CE Mark
Why Boston Scientific (BSX) Dipped More Than Broader Market Today
GE HealthCare (GEHC) Boosts Interventional Radiology Capabilities
Other News for BSX
Buy Rating Justified for Boston Scientific Amidst Positive TCAR Market Adoption and Growth Opportunities
Blackstone’s Voting Power in Corazon Diluted
7 Biotech Stocks to Boost Your Portfolio to Peak Health
3 Record-Breaking Stocks With More Room to Run
RBC Capital Remains a Buy on Boston Scientific (BSX)